Japan Acute Graft-versus-Host Disease (GVHD) Treatment Market Insight
Published: 08 August 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The Japan Acute graft-versus-host disease (GVHD) treatment market is expected to experience an increase at a rate of 9.1% to rising volumes of allogeneic hematopoietic stem cell transplantation, growing adoption of mesenchymal stem cell and biologic therapies for steroid-refractory disease, and expanding government reimbursement support for regenerative medicine products.
Japan Acute GVHD treatment Market Insights Forecasts to 2035
- The Japan Acute GVHD treatment Market Size was estimated USD 148.6 Million in 2025
- The market size is expected to grow at a CAGR of around 9.3% from 2025 to 3035
- The Japan Acute GVHD Treatment Market size is expected to rise to around USD 362.2 Million by 2035
Notable Insights for the Japan Acute GVHD Treatment Market
- The product-based segmentation indicates that the cell-based Therapies (Mesenchymal stem cell products) segment holds a commanding position with almost 46% market share in the Japan acute GVHD treatment market in 2025 due to the long clinical track record and established reimbursement of MSC-based therapies such as TEMCELL HS Inj., approved under Japan's regenerative medicine regulatory framework.
- The Application-based segmentation shows that the steroid-refractory acute GVHD treatment segment dominates with a market share of almost 54% int he Japan Acute GVHD treatment market in 2025 as a result of limited first-line corticosteroid response rates and increasing use of second-line cell-based and immunomodulatory therapies
- JCR Pharmaceuticals Co., Ltd. Reported first-Quarter fiscal 2025 sales of TEMCELL HS Inj. of approximately JPY 845 million,year on year increase of about 15.8% reflecting steady demand growth for MSC-based acute GVHD Treatment in Japan.
- As per expectations, rising adoption of JAK-inhibitor and cell-based combinations protocols along with growing hematopoietic stem cell transplant volumes will drive market expansion in which advanced acute GVHD treatment approaches reduce steroid-refractory disease progression up to 35% and improve day-100 post transplant survival outcomes up to 28%
Download the eBook (ToC)
Research Methodologies used to analyze the Japan Acute GVHD treatment Market
The Japan acute GVHD treatment market is analyzed by a blend of primary and secondary research approaches to ensure accurate information about the market and its forecasted performance. Primary research is conducted through discussions with pharmaceutical manufacturers and distributors, transplant centers, hematology and oncology departments, regulatory bodies, and clinical experts to analyze demand trends, treatment adoption patterns, and competitive activities. Secondary research will involve analyzing reports published by companies and government agencies, industry journals, scientific papers, clinical trial registries, and healthcare organizations in connection with hematopoietic stem cell transplantation and regenerative medicine. Market estimation, trend analysis, and forecasting methods will be used for estimating market size, growth opportunities, pricing dynamics, and reimbursement trends.
Decisions Advisors Research Methodology: Trusted Insights for Strategic Decision-Making
What is Decisions Advisors Research?
Decisions Advisors research delivers comprehensive market intelligence through detailed industry analysis, competitive benchmarking, trend forecasting, and data-driven business insights. Our research methodology combines advanced analytical frameworks with extensive primary and secondary research to help organizations make informed and strategic business decisions.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Acute GVHD Treatment Market, along with a comparative evaluation primarily based on their product offerings, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Japan Acute GVHD Treatment Market
- JCR Pharmaceuticals Co., Ltd
- Mesoblast Limited
- Novartis Pharma K.K.
- Sanofi K.K
- Astellas Pharma Inc
- Kyowa Kirin Co., Ltd
- Takeda Pharmaceutical Company Limited
- Sumitomo Pharma Co., Ltd.
- CSL Behring K.K
- Others
Recent Developments:
- In May 2025, Mesoblast Limited's remestemcel-L (Ryoncil) received seven years of orphan drug status
- Exclusivity from the U.S. FDA for the treatment of steroid-refractory acute GVHD in pediatric patients, reinforcing global clinical confidence in the mesenchymal stem cell platform that also underpins TEMCELL HS Inj., its licensed equivalent marketed in Japan by JCR Pharmaceuticals
- In July 2025, JCR Pharmaceuticals Co., Ltd. was selected for Japan's Ministry of Economy, Trade and Industry Regenerative Medicine CDMO subsidy Program to expand biomanufacturing Capacity for regeerative, cell, and gene therapies, building on its expertise since TEMCELL HS Inj’s original 2015 approval.
Market Segmentation:
Japan Acute GVHD treatment Market, By product Type
- Cell-based therapies (Mesenchymal Stem Cell products)
- Corticosteroids
- JAK Inhibitors
- Monoclonal Antibodies & Biologics
- Other Immunosuppressive Agents
Japan Acute GVHD treatment Market, By Treatment Line
- First-Line Corticosteroid Therapy
- Second line/steroid -Refractory Therapy
- Cell-Based Salvage Therapy
- Combination Immunomodulatory Regimens
- Supportive & Prophylactic care
Japan Acute GVHD treatment Market, By Application
- Skin GVHD
- Gastrointestinal GVHD
- Hepatic GVHD
- Multi-organ/Overlap GVHD
- Pediatric Acute GVHD
Expert Views:
The growth of the acute GVHD treatment market in Japan will be facilitated by rising volumes of allogeneic hematopoietic stem cell transplantation, increasing use of mesenchymal stem cells and biologic therapies, and higher demand for effective second-line treatment options among steroid-refractory patients. The use of cell-based regenerative therapies, JAK-inhibitor regimens, and improved diagnostic and monitoring protocols will continue to improve transplant outcomes and enhance demand across university hospitals, speciality transplant centers, and clinical research institutions in Japan.
Author: Govind and Krishna By Decisions Advisors and Consulting